// App-Quantinova.ai

2325 : Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Efficacy and Safety Results of the Phase 3 Candor Study

Researchers

Presenter

  • Meletios A Dimopoulos

Principal Investigators

  • Hang Quach

  • Mara-Victoria Mateos

  • Ola Landgren

  • Xavier Leleu

  • David S. Siegel

  • Katja Weisel

  • Maria Gavriatopoulou

  • Albert Oriol

  • Neil K Rabin

  • Ajay Nooka

  • Ming Qi

  • Bifeng Ding

  • Anita Zahlten-Kumeli

  • Saad Z. Usmani

Medical Centers

  • Athens School of Medicine, Athens, Greece

  • Melbourne Blood Specialist, East Melbourne, VIC, Australia

  • Institute of Cancer Molecular and Cellular Biology,University Hospital of Salamanca,Salamanca,Spagna

  • Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

  • CHU de Poitiers - Hôpital La Milétrie, Service d'Hématologie et Thérapie Cellulaire, Pôle Régional de Cancérologie, POITIERS, France

  • Hackensack Univ Med Ctr, Hackensack, NJ

  • Department of Neurosurgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

  • Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Alexandra General Hospital, Athens, Greece

  • Institut Catala dOncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Barcelona, Spain

  • University College London Hospitals NHS Trust, London, United Kingdom

  • Winship Cancer Institute of Emory University, Atlanta, GA

  • Janssen Research and Development, LLC, Spring House, PA

  • Amgen Inc., 1 Amgen Center Drive, CA

  • Amgen Inc, Thousand Oaks, CA

  • Levine Cancer Institute, Charlotte, SC

  • Atrium Health, Charolotte

Locations

  • Greece

  • Australia

  • Spain

  • United States

  • France

  • Germany

  • United Kingdom

Companies

  • Amgen Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • N/A

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • carfilzomib Intravenous

  • daratumumab Intravenous

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

Phase

  • III

Study Id's

  • NCT03158688

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved